Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial
- DOI
- 10.1016/j.esmoop.2026.106089
- Published
- 2026-03
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.106089,
title = {Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial},
author = {J. Bedke and M.S. van der Heijden and G. Sonpavde and M.D. Galsky and W. Liao and L. Shi and S.I. Blum and S. Mitra and M.Y. Patel and T. Powles},
year = {2026},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2026.106089},
url = {https://doi.org/10.1016/j.esmoop.2026.106089}
}RIS
TY - JOUR TI - Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial AU - J. Bedke AU - M.S. van der Heijden AU - G. Sonpavde AU - M.D. Galsky AU - W. Liao AU - L. Shi AU - S.I. Blum AU - S. Mitra AU - M.Y. Patel AU - T. Powles PY - 2026 JO - ESMO Open DO - 10.1016/j.esmoop.2026.106089 UR - https://doi.org/10.1016/j.esmoop.2026.106089 ER -
APA
Bedke, J., Heijden, M. V. D., Sonpavde, G., Galsky, M., Liao, W., Shi, L., Blum, S., Mitra, S., Patel, M., & Powles, T. (2026). Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.106089
Source records
- crossref · retrieved 2026-09-25T07:45:42.913Z